Substudy 02B
Stage/indication incl. Brief info
Melanoma - 1st line
Stage III or IV
Anti-PD1 + antiTIGIT vs anti-PD1 + antiCTLA4 vs anti-PD1 + antiCTLA4 + lenvatinib vs anti-PD1
Short title
Merck MK3475
Substudy 02B
(UmbrellaTrial)
NCT04305054
Official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02B